Telik
21
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
23.8%
5 terminated/withdrawn out of 21 trials
76.2%
-10.3% vs industry average
19%
4 trials in Phase 3/4
0%
0 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
Role: lead
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Role: lead
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
Role: lead
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia
Role: lead
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Role: lead
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Role: lead
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Role: lead
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Role: lead
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Role: lead
Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
Role: lead
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Role: lead
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Role: lead
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
Role: lead
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Role: lead
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
Role: lead
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Role: lead
Phase 2 Study of TLK286 in Metastatic Breast Cancer
Role: lead
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Role: lead
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Role: lead
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
Role: lead